Docstoc

Simple Joint Venture Agreement

Document Sample
Simple Joint Venture Agreement Powered By Docstoc
					Company Name                 ArBlast Co. Ltd.,
Address                      Kobe International Business Center, 5-5-2 Minatojima-minamimachi, Chuo-ku, Kobe 650-0047
Contact person               Nobuyuki Shima
Title                        General Maneger
TEL                          +81-78-304-5870
FAX                          +81-78-304-5871
URL                          http://www.arblast.jp
E-mail address               info@arblast.jp
Paid-in capital (JPY)        846,375,000
Paid-in capital (USD)        7,408,744
No. of employees             46
Year of establishment        Dec. 27, 2000
Company overview (max.       ArBlast was established in December 2005 through the merger of two
150 words)                   companies that has been engaged in innovative research and
                             development activities in the field of regenerative medicine.
                             As a regenerative medicine venture business involved in developing the
                             largest number of items in this field in Japan, we hope to actively take on
                             the challenges of this new business area and create a pioneer group in
                             the medical industry. Only after addressing these challenges, which no
                             one has ever tracked before, and working toward our vision, we firmly
Specific technological
fields and/or development
phase in which you are
interested in partnering
(max. 150 words)

Type of deals you are         ■Out-licensing                         □Research Agreement
interested in (check all that □In-licensing                          □Distribution
apply)                        □Joint Venture                         ■Other
Deal details (target
companies/industries,
exclusive territories, etc.)
       (max. 250 words)




                                                     -1-
Company Name                  Aspiron Co.,Ltd.
Address                       1-22 Suketobashi, Tokushima-shi, Tokushima 770-0815, JAPAN
Contact person                Takeru Fujii
Title                         the Chief Executive Officer
TEL                           +81-088-656-0190
FAX                           +81-088-656-8727
URL                           http://www.aspion.co.jp
E-mail address                info@aspion.co.jp
Paid-in capital (JPY)         436,642,500
Paid-in capital (USD)         US$4,363,425.00-
No. of employees              8
Year of establishment         2004
Company overview (max.         As for Aspiron Co., Ltd., the protein and the compound etc. of hydrophile and the
150 words)                    insolble plan the stabilization of the medicine by an original technology, and offer
                              the development of the medicine that improves absorption in addition from the
                              research to the clinical development sample manufacturing.Moreover, please
                              consult about any our company as the first CMO organization concerning
                              development like not only the drug product but also the animal examination, the
                              analysis, and the design of the device, etc. domestically.
Specific technological         Aspiron Co., Ltd. starts from the drug product research by an original drug product
fields and/or development     technology named Solid-in-oil (S/O), and does the investigational new drug
phase in which you are        manufacturing that uses its company GMP facilities in Kobe R&D center of the
interested in partnering      completion schedule of current year.
(max. 150 words)                                                        -Improvement of absorption of medicine
                              with difficult absorption.
                              -Turning protein and peputide into oral medicine.
                              -Development of medicine made of passing skin absorption.
                                                                                               -Development
                              of medicine that uses device (passing nose, passing lungs, and fixed-quantity
Type of deals you are         ■Funding
interested in (check all that □Out-licensing
apply)                        □In-licensing
                              □Joint Venture
Deal details (target          Target companies: Pharmaceutical companies, cosmetic companies, food
companies/industries,         companies
exclusive territories, etc.)
       (max. 250 words)




                                                     -2-
 Tokushima 770-0815, JAPAN




 n and the compound etc. of hydrophile and the
e medicine by an original technology, and offer
hat improves absorption in addition from the
nt sample manufacturing.Moreover, please
 the first CMO organization concerning
  product but also the animal examination, the
 ice, etc. domestically.
rug product research by an original drug product
 ), and does the investigational new drug
 ny GMP facilities in Kobe R&D center of the
ar.
       -Improvement of absorption of medicine

oral medicine.
f passing skin absorption.
                             -Development
ing nose, passing lungs, and fixed-quantity
              □Research Agreement
              ■Distribution
              □M&A
              ■Other
l companies, cosmetic companies, food




                                                   -2-
Company Name                 Carna Biosciences, Inc.
Address                      KIBC511, 5-5-2, Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047
Contact person               Hiroshi Ishiguro, Ph.D.
Title                        Chief Technology Officer
TEL                          (+)81-78-302-7091
FAX                          (+)81-78-302-7086
URL                          http://www.carnabio.com
E-mail address               hiroshi.ishiguro@carnabio.com
Paid-in capital (JPY)        1,521,700,000
Paid-in capital (USD)        US$13 million
No. of employees             32
Year of establishment        2003
Company overview (max.       In 2003, Carna Biosciences was established as a spin-off biotechnology
150 words)                   venture company of a research unit of a major pharmaceutical company.
                             Our mission is to conduct drug discovery programs with a focus on cellular
                             signaling as well as to provide drug discovery supporting services to
                             pharmaceutical companies with our proprietary technologies.
Specific technological        Carna Biosciences provides drug discovery supporting services to
fields and/or development     pharmaceutical companies. With our proprietary technologies in gene
phase in which you are        cloning, active kinase protein expression, protein purification and
interested in partnering      homogeneous assay development, we have succeeded in producing more
(max. 150 words)              than 230 protein kinases. Utilizing these technologies and know-how, we
                              also conduct own drug discovery programs targeting kinases.
Type of deals you are         □Out-licensing                      ■Research Agreement
                                                                  0
interested in (check all that □In-licensing                       □Distribution
apply)                        □Joint Venture                      □Other
Deal details (target          From small businesses to large pharmaceutical and biotechnology
companies/industries,         companies.
exclusive territories, etc.)
       (max. 250 words)




                                                 -3-
Company Name                  Cosmos Corporation
Address                       319 Akeno, Obata-cho, Ise-shi, Mie 519-0501 JAPAN
Contact person                Yoshihiro Sato
Title                         Business Planning Staff
TEL                           +81-596-37-0190
FAX                           +81-596-37-3609
URL                           http://www.safetyweb.co.jp
E-mail address                sales@cosmos-corp.com
Paid-in capital (JPY)         30,000,000JPY
Paid-in capital (USD)         US$ 260,870.00-
No. of employees              200
Year of establishment         1987
Company overview (max.        Cosmos Corporation's main lines of business are applications for
150 words)                    world safety approval for electrical products and components,
                              evaluation testing and EMC measurement services. In the field of
                              medical devices, Cosmos Corporation was accredited as a third
                              party certification body by the Ministry of Health, Labour and
                              Welfare of Japan on April 1, 2005 in accordance with the amended
                              Pharmaceutical Affairs Law. Cosmos Corporation also performs
                              evaluation testing of medical devices in accordance with a wide
                              range of JIS standards.
                              Cosmos Corporation can offer "one-stop" service covering every
                              step from evaluation testing to certification to manufacturers of
                              medical devices for Japanese market.
Specific technological        □Funding                            □Research Agreement
Type of deals you are         □Out-licensing                      □Distribution
interested in (check all that □In-licensing                       □M&A
apply)                        □Joint Venture                      ■Other
Deal details (target          Manufacturers of medical devices marketed in Japan
companies/industries,
exclusive territories, etc.)
       (max. 250 words)




                                                -4-
Company Name                 Medical Consulting & Research Institute Co., Ltd. (MCRI)
Address                      3 Chome Kobayashi Bldg. 2F 3-19-13, Akasaka, Minato-Ku,Tokyo,107-0052 Japan
Contact person               Mr.Tositugu Kashiwagi
Title                        CEO/President
TEL                          Tel; +81-3-5573-8576
FAX                          Fax; +81-3-5573-2410
URL                          URL;http;/www.mcri.co.jp
E-mail address               t-kashiwagi@mcri.co.jp
Paid-in capital (JPY)        10,000,000-
Paid-in capital (USD)        $86,580-
No. of employees             10 employees
Year of establishment        2000
Company overview (max.       MCRI is one of a handful of consurting reserch companies specializing in
150 words)                   healthcare. We conduct objective, scientific research on pharmaceuticals,
                             clinical-diagonostic products and medical devices through all steps, from
                             R&D through product launch and post-marking evaluation, to enable you to
                             comfirm and fine-tune the direction of product development, redevelop
                             plans, evaluate marketing concepts and maximise risk management.
Specific technological       Consulting research is useful for determining the direction and focus of
fields and/or development    product development. MCRI's specialist medical researchers, analysts and
phase in which you are       consultants choose the most appropriate research methodology for the
interested in partnering     objectives of the study and can supply your research needs at all stage,
(max. 150 words)             from R&D throuh product launch.
Type of deals you are         □Out-licensing                   □Research Agreement
interested in (check all that □In-licensing                    □Distribution
apply)                        □Joint Venture                   ■Other
Deal details (target          Consulting & research
companies/industries,
exclusive territories, etc.)
       (max. 250 words)




                                                -6-
Company Name                   Kobe Biomedix Co., Ltd.
Address                        (Kobe Office)7‐1‐16 Minatojima Minami‐cho, Chuo‐ku, Kobe, 650‐0047 Japan
Contact person                 Katsuya Onishi
Title
TEL                            078-304-5067
FAX                            078-304-5068
URL                            http://kobe-biomedix.co.jp
E-mail address                 kbm@sepia.ocn.ne.jp
Paid-in capital (JPY)          18,400,000
Paid-in capital (USD)
No. of employees               7
Year of establishment          2003
Company overview (max.         Kobe BioMedix Co., Ltd. actively promotes connecting recognized manufacturing
150 words)                     technologies held by shareholding companies to the needs of medical insstitutions
                               for development of new medical equipment. We hope tp play a part in expanding the
                               role of small and medium sized enterprises in the 21th century.


Specific technological        1. Purchase, sale, research, development of medical equipment.
fields and/or development     2. Receiving orders for desig, manufacturing, maintenance, etc. of medical
phase in which you are        equipment, serving as a proxy for placing orders.
interested in partnering      3. Providing services for the collection and distribution of information related to
(max. 150 words)              medical equipment.
                              4. Providing consulting services for the permission application for medical
                              equipment under the Pharmaceutical Affairs Law.
Type of deals you are         □Out-licensing
interested in (check all that □In-licensing
apply)                        ■Joint Venture
Deal details (target           Target companies: Medical equipment sales companies
companies/industries,
exclusive territories, etc.)
       (max. 250 words)




                                                      -9-
-9-
ojima Minami‐cho, Chuo‐ku, Kobe, 650‐0047 Japan




 vely promotes connecting recognized manufacturing
 olding companies to the needs of medical insstitutions
dical equipment. We hope tp play a part in expanding the
zed enterprises in the 21th century.


 development of medical equipment.
g, manufacturing, maintenance, etc. of medical
xy for placing orders.
 collection and distribution of information related to

ces for the permission application for medical
aceutical Affairs Law.
                ■Research Agreement
                □Distribution
                □Other
equipment sales companies




                                                           -9-
-9-
Company Name               M&E Scientifics
Address                    3-1-14 Msakihonmach, Hyogoku, Kobe, Hyogo
Contact person             Masaaki Ando
Title                      sales
TEL                        81-78-672-0885
FAX                        81-78-651-3696
URL                        http://www.mes-kibc.co.jp
E-mail address             info@mes-kibc.co.jp
Paid-in capital (JPY)      3,000,000
Paid-in capital (USD)      US$ 30,000
No. of employees           5
Year of establishment      2003
Company overview (max.     We provide flexible automation system in the laboratory, using 5 axing
150 words)                 handling robot, dispenser, heat sealer, manual sealer and the other
                           automatic equipment. Combination and installation of them are free
                           according to the customers requirements. Easy operation, simple user
                           interface for programming and smaller footprint will be satisfactory to
                           the users.
Specific technological     Based on 60 years excellent "Manufacturing" technology for industrial
fields and/or development  filed which has been guaranteed by parent company, Showa Seiki
phase in which you are     Co., Ltd. We supply various instruments for lab. Automation System
interested in partnering   on demand.
(max.of deals you are
Type 150 words)               □Out-licensing                     □Research Agreement
interested in (check all that □In-licensing                      □Distribution
apply)                        □Joint Venture                     ■Other
Deal details (target          Pharmaceutical companies and research laboratories of food and
companies/industries,         cosmetics industry, inspection of medical treatment inspecting
exclusive territories, etc.) agency, basic
        (max. 250 words)      research                                    
                              laboratories such as
                              universities.                                       
                                          Physics and chemistry equipment trading company




                                                 -10-
Company Name                    Senju Pharmaceutical Co., Ltd.
Address                         2-5-8 Hiranomachi, Chuo-Ku, Osaka, 541-0046, Japan
Contact person                  Shinya Ogino
Title                           Manager, Corporate Business Development
TEL                             +81-6-6201-9698(dial-in)
FAX                             +81-6-6226-0406
URL                             http://www.senju.co.jp/english/
E-mail address                  s-ogino@senju.co.jp
Paid-in capital (JPY)           1.42 billion
Paid-in capital (USD)           (US$12.0 million)                 (US$1=118)
No. of employees                650
Year of establishment           1947
Company overview (max.          Senju Pharmaceutical is a well experienced pharmaceutical company
150 words)                      focused on the development and commercialization of products in the field
                                of ophthalmology. With its know-how and technologies, the company is
                                dedicated to research and develop innovative and unique ophthalmic
                                products for the treatment of eye diseases. As establishing global
                                partnerships, the comapany is active not only in Japan but worldwide.
                                We seek and welcome a variety of partnerships and cooperative business
                                opportunities to enhance our pipline and product lineup.

Specific technological          -Screening and researching candidate compounds and technologies for
fields and/or development       ophthalmic use.
phase in which you are          -Researching, developing, manufacturing and commercializing ophthalmic
interested in partnering        proudcts.
(max. 150 words)
Type of deals you are           ■Out-licensing                  ■Research Agreement
interested in (check all that   ■In-licensing                   □Distribution
apply)                          □Joint Venture                  □Other
Deal details (target            Target companies: Pharmaceutical companies, biotech companies,
companies/industries,           biopharmaceutical companies
exclusive territories, etc.)
        (max. 250 words)




                                                    -12-
Company Name                Sumitomo Bakelite Co., Ltd.
Address                     1-5, Murotan 1-Chome, Nishi-ku, Kobe, 651-2241, Japan
Contact person              Kent Fujiwara
Title                       Bio Product Development Project Team Leader
TEL                         +81-78-992-3949
FAX                         +81-78-992-3919
URL                         http://www.sumibe.co.jp/sumilon/s-bio/index.html
E-mail address              s-bio@sumibe.co.jp
Paid-in capital (JPY)       28,766,000,000Yen
Paid-in capital (USD)       US$ 287,660,000-
No. of employees            7,849
Year of establishment       1955
Company overview (max.      We develop the Bio products through our sophisticated plastics
150 words)                  technology. Our products should contribute to life science. Products are
                            biochips such as DNA chip and the protein chip, Oligosaccharide
                            Purification Kit, Cell Culture with Artificial Extracellular matrix , Nerve Cell
                            Culture System. The business target are Genome, Proteorm, Tissue
                            engineering.
Specific technological      1. DNA microarray with exream high S/N ratio
fields and/or development
phase in which you are               2. New SNPS Typing
interested in partnering      3. Protein microarray with extream high S/N ratio
(max. 150 words)              4. Plastic Microfluidics
                              5. New Cell Culture System
Type of deals you are         □Out-licensing                                  
                                                                 ■Research Agreement
interested in (check all that □In-licensing                      ■Distribution
apply)                        □Joint Venture                     □Other
Deal details (target          Target companies: Pharmaceutical companies, biotech companies,
companies/industries,         biopharmaceutical companies
exclusive territories, etc.)
       (max. 250 words)




                                              -13-
Company Name                Tissue Engineering and Cell Therapy Foundation for Biomedical research
                            and Innovation
Address                     TRI 308 1-5-4, Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, JAPAN
Contact person              dhin Kawamata, M.D., Ph. D.
Title                       Senior Research Scientist
TEL                         +81-78-306-0680
FAX                         +81-78-306-0679
URL                         http://www.ibri-kobe.org
E-mail address              kawamata@fbri.org
Paid-in capital (JPY)
Paid-in capital (USD)
No. of employees
Year of establishment
Company overview (max.      The Laboratory for Tissue Engineering and Cell Therapy in the FBRI
150 words)                  focuses on regenerative medicine and drug discovery for ischemic
                            cardiovascular disease utilizing DNA chip data base. Our lab also studies ex
                            vivo expansion of cord blood stem cells as cell source for regenerative
                            medicine. Further we developed the time-lapse culture cell monitoring
                            device for the quality control in the cell processing plant and for the high
Specific technological      Laboratory drug screening.
                            through putfor Tissue Engineering and Cell Therapy FBRI focuses on
fields and/or development   regenerative medicine, drug discovery, and monitoring device. We can
phase in which you are      provide the following technique:
interested in partnering
(max. 150 words)
                              Drug discovery for ischemic heart
                              Regenerative medicine for chronic heart failure
                                               Expansion of cord blood stem cell ex vivo
Type of deals you are         □Foundation                            ■Research Agreement
interested in (check all that □Out-licensing                         □Distribution
apply)                        □In-licensing                          □M&A
                              □Joint Venture                         □Other
Deal details (target          Target companies: Pharmaceutical companies, biotech companies,
companies/industries,         biopharmaceutical companies
exclusive territories, etc.)
       (max. 250 words)




                                                -14-
Company Name                    Trans Genic Inc.
Address                         7-1-14 Minatojimaminami-machi, Chuo-ku, Kobe, 650-0047 Japan
Contact person                  Isao Fukuda
Title                           Marketing Group, Group Leader
TEL                             +81-78-306-0295
FAX                             +81-78-306-0296
URL                             http://www.transgenic.co.jp
E-mail address                  fukuda@transgenic.co.jp
Paid-in capital (JPY)           4,855,000,000
Paid-in capital (USD)           US$ 40,458,000.00-                   (USD 1 = JPY 120)
No. of employees                45
Year of establishment           1998
Company overview (max.        TRANS GENIC INC. provides innovative tools for the exploration of drugable
150 words)                    targets, using the technology to produce genetically engineered mice and antibodies.
                              We have established a large-scale Knockout mice library, and provide valuable
                              resultant information on gene functions. We also provide high-affinity antibody
                              producing technology useful for the development of antibody medicines and
                              diagnostic agents.
Specific technological        1. Technology to produce genetically engineered mice.
fields and/or development - A large-scale, cyclopaedical KO mice library, produced through gene trapping.
                               - Reproduction engineering technology, such as the production of chimera mice
phase in which you are
                              and in-vitro fertilization.
interested in partnering      2. High-affinity antibody producing technology (germinal center associated nuclear
(max. 150 words)              protein—GANP technology)
                               - Creation of high affinity antibodies using GANP gene-modified mice.
                              3. Urine cancer marker
                               - A new urine cancer marker using anti-diacetylspermine antibody.
Type of deals you are         ■Out-licensing                           □Research Agreement
interested in (check all that ■In-licensing                            □Distribution
apply)                        □Joint Venture                           □Other
Deal details (target          We support your research by providing our innovative technologies, “Knockout mice
companies/industries,         production” and “High-affinity antibody production”. We also look for the new
exclusive territories, etc.) technologies which can achieve synergistic effects in collaborating with our
                              technologies.
       (max. 250 words)
                                Target Companies: Pharmaceutical companies, diagnostic reagent manufacturers,
                                biotech companies, biopharmaceutical companies




                                                    -15-

				
DOCUMENT INFO
Description: Simple Joint Venture Agreement document sample